Familial Creutzfeldt–Jakob disease (fCJD) is a hereditary prion disorder caused by pathogenic mutations in the prion protein gene (PRNP). It follows an autosomal dominant inheritance pattern and accounts for about 10–15 % of all CJD cases. Mutations such as E200K, V210I, D178N and V180I destabilise the cellular prion protein (PrP^C) and predispose it to convert into the misfolded, β‑sheet‑rich isoform (PrP^Sc). Once formed, PrP^Sc seeds the conversion of additional PrP^C, accumulates in neurons and astrocytes and causes spongiform degeneration, neuronal loss and glial proliferation.
Genetics, Clinical Features and Diagnosis
More than 50 pathogenic PRNP mutations have been described in fCJD. The E200K mutation is the most common worldwide and is especially prevalent among Libyan Jews and Slovak families. The V210I and V180I mutations are found mainly in European and Japanese populations, respectively. Age of onset varies with mutation, typically ranging from the late 30s to the 70s, and penetrance may be high but incomplete. Clinically, fCJD resembles sporadic CJD with rapidly progressive dementia, ataxia, myoclonus, extrapyramidal signs and akinetic mutism, but disease duration may be slightly longer in some families. Polymorphism at codon 129 of PRNP (methionine or valine) influences phenotype and age of onset. Diagnostic evaluation involves the same tools as for sCJD—MRI, EEG, CSF biomarkers and RT‑QuIC—combined with genetic testing to identify PRNP mutations. Brain biopsy or autopsy remains definitive. There is no curative treatment; management focuses on symptom control and palliative care.
Epidemiology and Genetic Counselling
fCJD is rare, with an estimated incidence of one case per ten million people per year. Clusters occur in certain ethnic groups due to founder mutations; for example, the E200K mutation has led to an unusually high incidence of CJD in Libyan Jewish communities in Israel and among Slovakian families in the Orava region. Transmission between individuals by usual social contact does not occur; however, iatrogenic transmission can theoretically arise from exposure to surgical instruments contaminated with prion-infected tissue. Genetic counselling and testing are crucial for at-risk relatives, as identification of the pathogenic mutation allows carriers to make informed reproductive and medical decisions. Prenatal diagnosis is technically possible, but ethical considerations must be addressed. Recognising fCJD underscores the importance of genetic mutations in prion diseases and highlights the need for targeted surveillance and counselling in affected families. Related Terms: Sporadic Creutzfeldt–Jakob Disease, Iatrogenic Creutzfeldt–Jakob Disease, Variant Creutzfeldt–Jakob Disease, Fatal Familial Insomnia, Gerstmann–Sträussler–Scheinker Syndrome